Auro Laboratories Ltd Financial Ratios
AUROLAB · Healthcare · Current price ₹234.7
P/E ratio
41.4x
P/B ratio
3.5x
ROE
7.6%
ROCE
8.3%
Debt / Equity
1.37
Dividend yield
0.0%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 41.4x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 3.5x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 7.6% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 8.3% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 1.37 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Auro Laboratories Ltd's latest numbers.
Auro Laboratories Ltd profitability
Auro Laboratories Ltd generates a return on equity of 7.6% and a return on capital employed of 8.3%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 1.37 and a P/E of 41.4x, Auro Laboratories Ltd is moderately leveraged. Our overall business-quality score for the company is 3.5 / 10.
Understand the ratios
More on Auro Laboratories Ltd
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.